263 related articles for article (PubMed ID: 34052583)
41. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
42. Enhanced antimicrobial activity and physicochemical stability of rapid pyro-fabricated silver-kaolinite nanocomposite.
Awad ME; López-Galindo A; Medarević D; Milenković M; Ibrić S; El-Rahmany MM; Iborra CV
Int J Pharm; 2021 Apr; 598():120372. PubMed ID: 33621641
[TBL] [Abstract][Full Text] [Related]
43. A natural antioxidant, tannic acid mitigates iron-overload induced hepatotoxicity in Swiss albino mice through ROS regulation.
Basu T; Panja S; Shendge AK; Das A; Mandal N
Environ Toxicol; 2018 May; 33(5):603-618. PubMed ID: 29446234
[TBL] [Abstract][Full Text] [Related]
44. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
Yang LP; Keam SJ; Keating GM
Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
[TBL] [Abstract][Full Text] [Related]
45. The targeted antibacterial and antifungal properties of magnetic nanocomposite of iron oxide and silver nanoparticles.
Prucek R; Tuček J; Kilianová M; Panáček A; Kvítek L; Filip J; Kolář M; Tománková K; Zbořil R
Biomaterials; 2011 Jul; 32(21):4704-13. PubMed ID: 21507482
[TBL] [Abstract][Full Text] [Related]
46. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
47. Antimicrobial, Antioxidant and Larvicidal Activities of Spherical Silver Nanoparticles Synthesized by Endophytic Streptomyces spp.
Fouda A; Hassan SE; Abdo AM; El-Gamal MS
Biol Trace Elem Res; 2020 Jun; 195(2):707-724. PubMed ID: 31486967
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
49. Green Synthesis of CuFe
Kahzad N; Salehzadeh A
Biol Trace Elem Res; 2020 Nov; 198(1):359-370. PubMed ID: 32067154
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
[TBL] [Abstract][Full Text] [Related]
51. Apoptosis induction in colon cancer cells (SW480) by BiFe
Golrokh FJ; Tolami HF; Ghanbarirad M; Mahmoudi A; Tabassi NR; Alkinani TA; Taramsari SM; Aghajani S; Taati H; Akbari F; Noveiri MJS; Hedayati M; Ghasemipour T; Salehzadeh A
J Trace Elem Med Biol; 2024 May; 83():127369. PubMed ID: 38176316
[TBL] [Abstract][Full Text] [Related]
52. A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice.
Kumfu S; Khamseekaew J; Palee S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Free Radic Res; 2018 Jan; 52(1):70-79. PubMed ID: 29207893
[TBL] [Abstract][Full Text] [Related]
53. Biogenic iron-silver nanoparticles inhibit bacterial biofilm formation due to Ag
Cusimano MG; Ardizzone F; Nasillo G; Gallo M; Sfriso A; Martino-Chillura D; Schillaci D; Baldi F; Gallo G
Appl Microbiol Biotechnol; 2020 Jul; 104(14):6325-6336. PubMed ID: 32462243
[TBL] [Abstract][Full Text] [Related]
54. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
55. Biosynthesis of silver capped magnesium oxide nanocomposite using Olea cuspidata leaf extract and their photocatalytic, antioxidant and antibacterial activity.
Khan AU; Khan AU; Li B; Mahnashi MH; Alyami BA; Alqahtani YS; Alqarni AO; Khan ZUH; Ullah S; Wasim M; Khan QU; Ahmad W
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102153. PubMed ID: 33348075
[TBL] [Abstract][Full Text] [Related]
56. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
[TBL] [Abstract][Full Text] [Related]
57. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.
Casale M; Filosa A; Ragozzino A; Amendola G; Roberti D; Tartaglione I; De Michele E; Cozzolino D; Rispoli G; Palmieri F; Pugliese U; Scianguetta S; Signoriello G; Musallam KM; Perrotta S
Am J Hematol; 2019 Mar; 94(3):312-318. PubMed ID: 30489651
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
59. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
Dubourg L; Laurain C; Ranchin B; Pondarré C; Hadj-Aïssa A; Sigaudo-Roussel D; Cochat P
Pediatr Nephrol; 2012 Nov; 27(11):2115-2122. PubMed ID: 22527533
[TBL] [Abstract][Full Text] [Related]
60. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
